Status:
COMPLETED
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in...
Eligibility Criteria
Inclusion
- Hypertension
- Elevated urinary protein levels
- Confirmed type 2 diabetes
Exclusion
- Certain diseases
- Uncontrolled diabetes
- Type 1 diabetes
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
496 Patients enrolled
Trial Details
Trial ID
NCT00097955
Start Date
October 1 2004
End Date
April 1 2007
Last Update
May 17 2017
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Site
Québec, Canada
3
Investigative Site
Hillerød, Denmark
4
Investigative Site
Paris, France